Management of peripheral arterial disease in the elderly: Focus on cilostazol

Clinical Interventions in Aging

Volumn 3, Issue 1, 2008, Pages 17-23

  Falconer, Travis M ^a   Eikelboom, John W ^b   Hankey, Graeme J ^a   Norman, Paul E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Cilostazol; Intermittent claudication; Peripheral arterial disease; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; PENTOXIFYLLINE; PLACEBO; SIMVASTATIN;

ARTERY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIARRHEA; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXERCISE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTERMITTENT CLAUDICATION; LONG TERM CARE; PREVALENCE; REVIEW; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SMOKING CESSATION; THROMBOSIS; VASODILATATION; WEIGHT REDUCTION;

AGED; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; INTERMITTENT CLAUDICATION; PERIPHERAL VASCULAR DISEASES; PHOSPHODIESTERASE INHIBITORS; SMOKING; SMOKING CESSATION; TETRAZOLES;

EID: 42449091102     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Adler AI, Stevens RJ, Neil A, et al. 2002. UKPDS 59: Hyperglycaemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care, 25:894-9.
2. American Diabetes Association. 2003. Peripheral arterial disease in people with diabetes. Diabetes Care, 26:3333-41.
3. Antithrombotic Trialists' Collaboration. 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324:71-86.
4. Aronow WS. 2004. Management of peripheral arterial disease of the lower extremities in elderly patients. J Gerontol, 59A: 172-7.
5. Aronow WS. 2006. Drug treatment of peripheral arterial disease in the elderly. Drugs Aging, 23:1-12.
6. Beckman JA, Jaff MR, Creager MA. 2006. The United States Preventive Services Task Force Recommendation Statement on Screening for Peripheral Arterial Disease: More Harm Than Benefit? Circulation, 114:861-6.
7. Beebe HG, Dawson DL, Cutler BS, et al. 1999. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Int Med, 159:2041-50.
8. Blood pressure lowering treatment trialists' collaboration. 2003. Effects of different blood pressure-lowering regimeson major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet, 362:1527-35.
9. Bradbury AW. 2003. The role of cilostazol in the management of intermittent claudication. Int J Clin Pract, 57:405-9.
10. CAPRIE Steering Committee. 1996. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348:1329-39.
11. Cariski AT. 2001. Cilostazol: a novel treatment option in intermittent claudication. Int J Clin Pract, 119:11-18.
12. Dawson DL, Cutler BS, Hiatt WR, et al. 2000. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med, 109:523-30.
13. Dawson DL, Cutler BS, Meissner MH, et al. 1998. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial. Circulation, 98:678-86.
14. Dawson DL. 2001. Comparitive effects of cilostazol and other therapies for intermittent claudication. Am J Cardiol, 87:19D-27D.
15. Dormandy JA, Rutherford RB. 2000. Management of peripheral arterial disease. J Vasc Surg, 31: S1-S296.
16. Elam MB, Heckman J, Crouse JR, et al. 1998. Effect of novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol, 181:942-7.
17. Erez G, Leitersdorf E. 2007. The Rationale for Using HMG-CoA Reductase Inhibitors ('Statins') in Peripheral Arterial Disease. Eur J Vasc Endovasc Surg, 33:192-201.
18. Fowler B, Jamrozik K, Norman P, et al. 2002. Improving maximum walking distance in early peripheral arterial disease: randomised controlled trial. Austr J Physiother, 48:269-75.
19. Fowler B, Jamrozik K, Norman P, et al. 2002. Prevalence of peripheral arterial disease: persistence of excess risk in former smokers. Aust NZ J Pub Health, 26:219-24.
20. Garg PK, Tian L, Criqui MH, et al. 2006. Physical activity during daily life and mortality in patients with peripheral arterial disease. Circulation, 114:242-8.
21. Girolami B, Bernardi E, Prins MH, et al. 1999. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline or nafronyl: a meta-analysis. Arch Int Med, 159:337-45.
22. Hankey GJ, Norman PE, Eikelboom JW. 2006. Medical management of peripheral arterial disease. JAMA, 295:547-53.
23. Heart Outcome Prevention Evaluation Study Investigators. 2000. Effects of an angiotensin-converting-enzyme inhibitor, Ramapril, on cardiovascular events in high-risk patients. N Engl J Med, 342:145-53.
24. Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with sinivastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360:7-22.
25. Hiatt W. 2001. Medical treatment of peripheral arterial disease and claudication. N Engl J Med, 344:1608-21.
26. Hiatt WR, Hoag S, Hamman RF. 1995. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. Circulation, 91:1472-9.
27. Hobbs SD, Marshall T, Fegan C, et al. 2007. The effect of supervised exercise and cilostazol on coagulation and fibrinolysis in intermittent claudication: A randomised controlled trial. J Vasc Surg, 45:65-70.
28. Liu Y, Shakur Y, Yoshitake MM, et al. 2001. Cilostazol (Pleta1): a dual inhibitor of cyclic nucleotide phosphdiesterase type 3 and adenosine uptake. Cardiovac Drug Rev, 19:369-86.
29. Matousovic K, Grande JP, Chini CCS, et al. 1995. Inhibitors of cyclic nucleotide phophdiesterase isoenzymes type-III and type-IV suppress mitogensis of rat mesangial cells. J Clin Invest, 96:401-10.
30. McDermott MM, Greenland P, Liu K, et al. 2001. Leg symptoms in peripheral arterial disease. Associated clinical characteristics and functional impairment. JAMA, 286:1599-606.
31. Mehler P, Coll J, Estacio R, et al. 2003. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation, 107:753-6.
32. Money SR, Herd JA, Isaacsohn JL, et al. 1998. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg, 27:267-75.
33. Motoyashiki T, Morita T, Ueki H. 1996. Involvement of the rapid increase in cAMP content in the vandate-stimulated release of lipoprotein lipase activity from rat fat pads. Biol Pharmacol Bull, 19:1412-16.
34. Muntner P, Wildman RP, Reynolds K, et al. 2005. Relationship between HbAic level and peripheral arterial disease. Diabetes Care, 28:1891-7.
35. Naylor A, Webb J, Fowkes F, et al. 1988. Trends in abdominal aortic aneurysm surgery in Scotland (1971-1984). Eur J Vasc Surg, 2:217-21.
36. Newman AB, Shemanski L, Manolio TA, et al. 1999. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol, 19:538-45.
37. Norgren L, Hiatt WR, Dormandy JA, et al. 2007. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg, 33:S1-S75.
38. Otsuka. Otsuka 21-94-201. 1996b. A randoinised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. Internal report. Unpublished data.: Otsuka Pharmaceuticals.
39. Otsuka. Otsuka 21-95-201. 1996a. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. Internal Report. Unpublished data.: Ostuka Pharmaceuticals.
40. Pedersen TR, Kjekshus J, Pyorala K, et al. 1998. Effect of sinivastatin on ischemic signs and symptoms in the Scandanavian Simvastatin Survival Study (4S). Am J Cardiol, 81:333-5.
41. Pratt CM. 2001. Analysis of the cilostazol safety database. Am J Cardiol, 87:28D-33D.
42. Regensteiner JG, Ware JE, McCarthy WJ, et al. 2002. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related qualitiy of life in patients with interrridttent claudication due to peripheral arterial disease: Metanalysis of six randomized control trials. J Am Geriatric Soc, 50:1939-46.
43. Reilly MP, Mohler ER. 2001. Cilostazol: Treatment of intermittent claudication. Ann Pharmacother, 35:48-56.
44. Rendell M, Cariski AT, Hittel N, et al. 2002. Ciolstazol treatment of claudication in diabetic patients. Curr Med Res Opin, 18:479-87.
45. Selvin E, Erlinger T. 2004. Prevalence of and risk factors for peripheral arterial disease in the United States, Results from the National Health and Nutrition Examination Survey 1999-2000. Circulation, 110:738-743.
46. Shephard R, Balady G. 1999. Exercise as cardiovascular therapy. Circulation, 99:963-72.
47. Strandness DE, Dalman RL, Panian S, et al. 2002. Effect of cilostazol in patients with intermittent claudication: A randomized, double-blind, placebo-controlled study. Vasc Endovasc Surg, 36:83-91.
48. Takahashi S, Oida K, Fujiwara R, et al. 1992. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle in culture. J Cardiovasc Pharmacol, 20:900-6.
49. Thompson PD, Zimet R, Forbes WP, et al. 2002. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol, 90:1314-19.
50. Willgendael EM, Teijink JAW, Bartelink M-L, et al. 2004. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg, 40:1158-65.
51. Wind J, Koelemay MJW. 2007. Exercise therapy and the additional effect of supervision on exercise therapy in patients with intermittent claudication. Systematic review of randomised controlled trials. Eur J Vasc Endovasc Surg, 34:19.
52. Yusef S, Hawken S, Ounpuu S, et al. 2005. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet, 366:1640-9.